AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	4287	62-54-4

Description:

Molecule	Description
Synonyms: calcium acetate acetic acid calcium salt calcium diacetate calcium acetate anhydrous	a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer Molecular weight: 158.17 Formula: C4H6CaO4 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 40.13 ALOGS: ROTB: None

Molecule

Description

Synonyms:

calcium acetate
acetic acid calcium salt
calcium diacetate
calcium acetate anhydrous

a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer

Molecular weight: 158.17
Formula: C4H6CaO4
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 40.13
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
6	g	O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
May 6, 1982	FDA	B BRAUN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Calciphylaxis	72.93	14.42	22	7992	3354	90617079
Hypercalcaemia	63.78	14.42	39	7975	34201	90586232
Blood phosphorus increased	51.76	14.42	18	7996	4300	90616133
Nephrogenic systemic fibrosis	44.94	14.42	16	7998	4092	90616341
Dialysis	43.92	14.42	21	7993	11308	90609125
Chronic kidney disease-mineral and bone disorder	43.34	14.42	8	8006	140	90620293
Peritonitis bacterial	41.35	14.42	16	7998	5155	90615278
Peritonitis	40.72	14.42	24	7990	19681	90600752
Hypervolaemia	36.21	14.42	27	7987	32730	90587703
Chronic kidney disease	35.70	14.42	32	7982	50159	90570274
Haemodialysis complication	34.00	14.42	7	8007	220	90620213
End stage renal disease	33.57	14.42	16	7998	8555	90611878
Milk-alkali syndrome	30.55	14.42	9	8005	1264	90619169
Hypocalcaemia	30.11	14.42	27	7987	42341	90578092
Diarrhoea	29.01	14.42	161	7853	939029	89681404
Aplasia pure red cell	27.62	14.42	12	8002	5182	90615251
Death	26.86	14.42	95	7919	456456	90163977
Product dose omission issue	25.80	14.42	70	7944	291617	90328816
Haemoglobin decreased	25.67	14.42	49	7965	161907	90458526
Blood parathyroid hormone increased	25.25	14.42	10	8004	3427	90617006
Haemodialysis	24.47	14.42	13	8001	8734	90611699
Dialysis hypotension	22.72	14.42	5	8009	217	90620216
Systemic lupus erythematosus	21.95	14.42	3	8011	361893	90258540
Pulmonary calcification	21.39	14.42	5	8009	285	90620148
Sepsis	21.00	14.42	48	7966	179766	90440667
Azotaemia	20.99	14.42	10	8004	5338	90615095
Hyperparathyroidism secondary	19.64	14.42	7	8007	1794	90618639
Synovitis	19.38	14.42	3	8011	329749	90290684
Renal failure	17.59	14.42	37	7977	130970	90489463
Fungal peritonitis	17.42	14.42	5	8009	641	90619792
Drug intolerance	17.31	14.42	9	8005	447582	90172851
Anaemia	17.06	14.42	69	7945	352733	90267700
Back pain	16.93	14.42	64	7950	317111	90303322
Atrial flutter	16.88	14.42	11	8003	10747	90609686
Brown tumour	16.07	14.42	3	8011	56	90620377
Acute phase reaction	15.69	14.42	4	8010	328	90620105
Hyperparathyroidism	15.46	14.42	7	8007	3330	90617103
Pulmonary oedema	15.46	14.42	23	7991	62057	90558376
Treatment failure	15.29	14.42	4	8010	303924	90316509
Cardiac failure congestive	14.58	14.42	29	7985	98665	90521768
Plasma cell myeloma	14.54	14.42	18	7996	40810	90579623
Cerebrovascular accident	14.44	14.42	33	7981	123500	90496933

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Peritonitis bacterial	86.90	16.59	35	6823	6880	42607597
Nephrogenic systemic fibrosis	55.58	16.59	21	6837	3480	42610997
Respiratory tract infection bacterial	43.65	16.59	15	6843	1894	42612583
Calciphylaxis	38.03	16.59	12	6846	1161	42613316
Hypervolaemia	36.39	16.59	30	6828	23095	42591382
Dialysis	35.97	16.59	23	6835	11963	42602514
Peritonitis	35.38	16.59	27	6831	18606	42595871
Respiratory tract infection viral	35.21	16.59	15	6843	3391	42611086
Skin induration	28.58	16.59	11	6847	1916	42612561
Skin fibrosis	27.87	16.59	9	6849	938	42613539
Joint contracture	27.26	16.59	11	6847	2170	42612307
Haemodialysis	24.31	16.59	17	6841	10243	42604234
Choreoathetosis	22.61	16.59	8	6850	1101	42613376
Blood parathyroid hormone increased	21.63	16.59	9	6849	1918	42612559
Renal failure	21.40	16.59	61	6797	143665	42470812
Fractured skull depressed	21.36	16.59	4	6854	40	42614437
Cardiac arrest	19.90	16.59	50	6808	109270	42505207
Refractory cytopenia with unilineage dysplasia	19.69	16.59	6	6852	517	42613960
Aplasia pure red cell	19.66	16.59	13	6845	7153	42607324
Blood potassium increased	19.18	16.59	19	6839	18517	42595960
Testicular haemorrhage	19.02	16.59	5	6853	252	42614225
Haemorrhagic ovarian cyst	18.68	16.59	4	6854	82	42614395
Mental status changes	18.53	16.59	28	6830	42087	42572390
Skin hypertrophy	18.44	16.59	9	6849	2780	42611697
Hyperkalaemia	18.12	16.59	40	6818	80418	42534059
Scar	18.02	16.59	12	6846	6676	42607801
Skin tightness	17.27	16.59	8	6850	2202	42612275
End stage renal disease	17.19	16.59	17	6841	16541	42597936
Transferrin saturation increased	17.07	16.59	4	6854	125	42614352

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Peritonitis bacterial	127.37	13.92	47	12362	10486	110566404
Calciphylaxis	112.10	13.92	34	12375	4153	110572737
Nephrogenic systemic fibrosis	103.07	13.92	34	12375	5449	110571441
Peritonitis	81.88	13.92	49	12360	32558	110544332
Dialysis	66.85	13.92	36	12373	19583	110557307
Hypervolaemia	63.35	13.92	49	12360	49411	110527479
Haemodialysis	53.44	13.92	30	12379	17689	110559201
Hypercalcaemia	52.84	13.92	43	12366	46614	110530276
Respiratory tract infection bacterial	45.48	13.92	15	12394	2401	110574489
End stage renal disease	40.68	13.92	27	12382	21446	110555444
Death	39.52	13.92	169	12240	698700	109878190
Blood parathyroid hormone increased	37.22	13.92	15	12394	4233	110572657
Skin induration	36.73	13.92	15	12394	4380	110572510
Haemoglobin decreased	34.40	13.92	82	12327	248645	110328245
Joint contracture	33.40	13.92	12	12397	2479	110574411
Respiratory tract infection viral	32.53	13.92	15	12394	5863	110571027
Hypocalcaemia	31.88	13.92	38	12371	65328	110511562
Pulmonary calcification	31.03	13.92	8	12401	539	110576351
Renal failure	30.58	13.92	74	12335	226500	110350390
Chronic kidney disease	30.27	13.92	40	12369	76251	110500639
Haemodialysis complication	28.96	13.92	7	12402	362	110576528
Skin fibrosis	27.59	13.92	9	12400	1391	110575499
Product dose omission issue	27.51	13.92	89	12320	321693	110255197
Blood phosphorus increased	27.27	13.92	19	12390	16321	110560569
Blood potassium increased	26.31	13.92	25	12384	33224	110543666
Skin hypertrophy	25.21	13.92	12	12397	5035	110571855
Fungal peritonitis	24.04	13.92	8	12401	1317	110575573
Nephrogenic anaemia	23.23	13.92	11	12398	4566	110572324
Sepsis	23.14	13.92	85	12324	327261	110249629
Aplasia pure red cell	23.02	13.92	14	12395	9564	110567326
Fractured skull depressed	22.80	13.92	4	12405	40	110576850
Choreoathetosis	22.09	13.92	8	12401	1690	110575200
Anaemia	21.96	13.92	120	12289	546966	110029924
Therapeutic reaction time decreased	21.73	13.92	11	12398	5268	110571622
Arteriovenous fistula occlusion	21.54	13.92	6	12403	543	110576347
Transferrin saturation increased	21.38	13.92	5	12404	224	110576666
Skin tightness	21.10	13.92	11	12398	5602	110571288
Testicular haemorrhage	20.89	13.92	5	12404	248	110576642
Milk-alkali syndrome	20.80	13.92	8	12401	1997	110574893
Pulmonary oedema	20.66	13.92	39	12370	100620	110476270
Serum ferritin increased	20.30	13.92	14	12395	11833	110565057
Mental status changes	20.17	13.92	33	12376	76089	110500801
Cardiac arrest	19.19	13.92	57	12352	196696	110380194
Arteriovenous fistula operation	19.08	13.92	5	12404	359	110576531
Treatment failure	18.93	13.92	4	12405	277230	110299660
Ultrafiltration failure	18.49	13.92	5	12404	405	110576485
Hyperphosphataemia	18.34	13.92	15	12394	16366	110560524
Hyperkalaemia	17.93	13.92	44	12365	135752	110441138
Groin infection	17.59	13.92	6	12403	1064	110575826
Hepatic enzyme increased	17.58	13.92	7	12402	320885	110256005
Azotaemia	17.47	13.92	12	12397	10073	110566817
Thoracic vertebral fracture	16.70	13.92	10	12399	6645	110570245
Drug intolerance	16.34	13.92	13	12396	406499	110170391
Cavernous sinus syndrome	16.30	13.92	3	12406	40	110576850
Unresponsive to stimuli	16.02	13.92	27	12382	63763	110513127
Hypotension	15.97	13.92	107	12302	523742	110053148
Anti-erythropoietin antibody positive	15.65	13.92	5	12404	724	110576166
Lower respiratory tract infection	15.62	13.92	4	12405	243102	110333788
Infusion related reaction	15.56	13.92	12	12397	381150	110195740
Sudden cardiac death	15.53	13.92	9	12400	5628	110571262
Refractory cytopenia with unilineage dysplasia	14.64	13.92	5	12404	890	110576000
Penile haemorrhage	14.57	13.92	5	12404	903	110575987
Arteriovenous fistula site haemorrhage	14.16	13.92	4	12405	381	110576509
Diarrhoea	14.09	13.92	192	12217	1139313	109437577
Renal transplant	14.07	13.92	7	12402	3231	110573659
Pulseless electrical activity	14.02	13.92	13	12396	16744	110560146
Arteriovenous fistula site complication	13.95	13.92	5	12404	1025	110575865
Hyperparathyroidism secondary	13.94	13.92	7	12402	3297	110573593

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE07	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
CHEBI has role	CHEBI:38161	chelator
CHEBI has role	CHEBI:176497	geroprotector
CHEBI has role	CHEBI:231911	renoprotective agent
MeSH PA	D002614	Chelating Agents
MeSH PA	D064449	Sequestering Agents

Related Drugs by ATC class:

V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia 10 drugs

calcium acetate and magnesium carbonate calcium polystyrene sulfonate colestilan ferric citrate lanthanum carbonate patiromer calcium sevelamer sodium polystyrene sulfonate sodium zirconium cyclosilicate sucroferric oxyhydroxide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypocalcemia	indication	5291005
Hyperkalemia	indication	14140009
Hypermagnesemia	indication	66978005
Hypocalcemic tetany	indication	190869004
Disorder of electrolytes	indication	237840007
Cardiac arrest	indication	410429000	DOID:0060319
Renal Osteodystrophy with Hyperphosphatemia	indication
Neonatal hypocalcemic tetany	off-label use	18442000
Poisoning by digitalis glycoside	contraindication	12876009
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Diarrhea	contraindication	62315008
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL CARE	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	8592480	July 20, 2027	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL CARE	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	9089528	July 20, 2027	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL CARE	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	8591938	Feb. 23, 2030	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018721	VUID
N0000147026	NUI
D00931	KEGG_DRUG
4018721	VANDF
C0717537	UMLSCUI
CHEBI:59199	CHEBI
CHEMBL1200800	ChEMBL_ID
DB00258	DRUGBANK_ID
C120662	MESH_SUPPLEMENTAL_RECORD_UI
Y882YXF34X	UNII
6116	PUBCHEM_CID
214342	RXNORM
118	MMSL
4329	MMSL
d03689	MMSL
000772	NDDF
116118002	SNOMEDCT_US
387019008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0088	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8632	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7119	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-629	CAPSULE	667 mg	ORAL	ANDA	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	16571-813	CAPSULE	667 mg	ORAL	ANDA	19 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0088	CAPSULE	667 mg	ORAL	ANDA	24 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0191	CAPSULE	667 mg	ORAL	ANDA	27 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0377	CAPSULE	667 mg	ORAL	ANDA	17 sections
calcium acetate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-531	CAPSULE	667 mg	ORAL	ANDA	22 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-621	TABLET	667 mg	ORAL	ANDA	16 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	29033-026	CAPSULE	667 mg	ORAL	ANDA	24 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	50268-203	CAPSULE	667 mg	ORAL	ANDA	29 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0621	TABLET	667 mg	ORAL	ANDA	16 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	53746-590	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0216	CAPSULE	667 mg	ORAL	ANDA	18 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0905	CAPSULE	667 mg	ORAL	NDA AUTHORIZED GENERIC	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	53808-1001	CAPSULE	667 mg	ORAL	ANDA	17 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	53808-1103	CAPSULE	667 mg	ORAL	ANDA	25 sections
Phoslo	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3460	CAPSULE	667 mg	ORAL	NDA	11 sections
Phoslo	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5691	CAPSULE	667 mg	ORAL	NDA	11 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4169	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60687-589	CAPSULE	667 mg	ORAL	ANDA	27 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	62135-191	CAPSULE	667 mg	ORAL	ANDA	27 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	62135-192	TABLET	667 mg	ORAL	ANDA	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	68084-479	CAPSULE	667 mg	ORAL	ANDA	25 sections
Eliphos	HUMAN PRESCRIPTION DRUG LABEL	1	68151-5204	TABLET	667 mg	ORAL	ANDA	25 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	68382-539	CAPSULE	667 mg	ORAL	ANDA	25 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	68382-642	TABLET	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-862	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69367-411	CAPSULE	667 mg	ORAL	ANDA	29 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

calcium acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: